In its second-quarter earnings release,Kezar Life Sciences Inc. (NASDAQ:KZR) announced that it had dropped its phase 1 solid tumor drug. The company said it stopped patient enrollment in the KZR-261 Phase 1 study, and clinical resources are being reallocated toward developing zetomipzomib in autoimmune hepatitis (AIH) and lupus nephritis (LN). Patients already enrolled in the study will continue to have access to KZR-261. A total of 61 patients were enrolled across the dose-escalation and expansion portions of the study, including seven patients enrolled in the melanoma cohort of the dose-expa…